COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Hydroxychloroquine 200 mg tablet, every 12 hours with Atazanavir / Ritonavir tablets daily for at least 5-7 days. Intervention 2: Control group: Hydroxychloroquine
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who are hospitalized in the ward and are considered to have a moderate form of COVID-19 (need to be admitted to the ward and not ICU hospital) Patients who are satisfied with the study entry
Exclusion criteria
Exclusion criteria: The patient has a severe disease that requires Ribavirin The patient need to be hospitalized in the ICU or intubation The patient has a mild form of the disease that does not require hospitalization (patients with a history of outpatient treatment for COVID-19). Patients with specific underlying disease and / or need to take specific medications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Oxygen saturation following combination therapy for COVID-19. Timepoint: Daily examination of the patient during hospitalization. Method of measurement: pulse oxymetry. | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment outcome (recovery rate). Timepoint: At the end of treatment and hospitalization. Method of measurement: physical examination and patient file.;Mortality rate. Timepoint: At the end of treatment and hospitalization. Method of measurement: patient file.;Complications of disease. Timepoint: At the end of treatment and hospitalization. Method of measurement: physical examination and patient file. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHossein Mazaherpour
Arak University of Medical Sciences
Outcome results
None listed